Chronic hepatitis C virus (HCV) infection is associated with renal dysfunction. Daclatasvir and asunaprevir combination therapy showed a high virological response for genotype 1 chronic HCV-infected patients with renal dysfunction on hemodialysis. However, the safety and efficacy of the therapy for patients with renal dysfunction who are not on hemodialysis are not well-known. In total, 147 patients with chronic HCV genotype 1 infection were treated with 24 weeks of daclatasvir plus asunaprevir therapy. Among these patients, 126 had normal renal function (estimated glomerular filtration rate [eGFR] ! 50 ml/min/1.73 m 2 ) and 21 had renal dysfunction (eGFR < 50 ml/min/ 1.73 m 2 ). Plasma concentrations of daclatasvir and asunaprevir after 5 days of treatment were the same in the normal renal function and renal dysfunction groups. Early virological response (4, 8, 48, 96, and 168 hr after the start of the therapy) was similar between the two groups.
Chronic hepatitis C virus (HCV) infection is associated with renal dysfunction. Daclatasvir and asunaprevir combination therapy showed a high virological response for genotype 1 chronic HCV-infected patients with renal dysfunction on hemodialysis. However, the safety and efficacy of the therapy for patients with renal dysfunction who are not on hemodialysis are not well-known. In total, 147 patients with chronic HCV genotype 1 infection were treated with 24 weeks of daclatasvir plus asunaprevir therapy. Among these patients, 126 had normal renal function (estimated glomerular filtration rate [eGFR] ! 50 ml/min/1.73 m 2 ) and 21 had renal dysfunction (eGFR < 50 ml/min/ 1.73 m 2 ). Plasma concentrations of daclatasvir and asunaprevir after 5 days of treatment were the same in the normal renal function and renal dysfunction groups. Early virological response (4, 8, 48, 96 , and 168 hr after the start of the therapy) was similar between the two groups.
End-of-treatment response was achieved in 122 (96.8%) and 20 (95.2%) patients with normal renal function and with renal dysfunction, respectively, and sustained virological response was achieved in 119 (94.4%) and 20 (95.2%) patients. The frequency of adverse events was also comparable between the two groups. Treatment discontinuation due to adverse events was required for only one patient in each group. Renal function did not change either during or after treatment in both groups. In conclusion, renal function is unlikely to have a significant impact on blood kinetics of daclatasvir and asunaprevir. This combination therapy was effective and safe for patients without hemodialysis. J. Med. Virol. 89:665-671, 2017 . # 2016 Wiley Periodicals, Inc.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is the leading cause of cirrhosis, liver failure, and hepatocellular carcinoma [Kiyosawa et al., 1990; Niederau et al., 1998 ]. Of particular interest is the fact that HCV is often accompanied by manifestations in organs other than the liver. The involvement of the kidneys is one of the most significant extrahepatic disorders of HCV and varies in frequency from 10% Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAA, direct-acting antiviral; eGFR, estimated glomerular filtration rate; ETR, end-of-treatment response; HCV, hepatitis C virus; IFNL, interferon lambda; ITPA, inosine triphosphatase; MPGN, membranoproliferative glomerulonephritis; NS, nonstructural protein; PEG-IFN, peginterferon; RAVs, drug resistance-associated variants; RBV, ribavirin; SNPs, single nucleotide polymorphisms; SVR, sustained virological response Grant sponsor: Japan Agency for Medical Research and Development, AMED; Grant number: 15fk0210001h0002
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Interferon has long been the backbone of HCV therapy, but even with the introduction of peginterferon (PEG-IFN) and ribavirin (RBV), sustained virological response (SVR) rates remained below 50% for genotype 1 infection despite 48 weeks of therapy and considerable risk of adverse events [Hadziyannis et al., 2004] . Since the route of RBV elimination is mainly by the kidney, the drug is contraindicated in patients with creatinine clearance less than 50 ml/min. Therefore, PEG-IFN monotherapy with dose reduction was recommended for treatment of chronic hepatitis C patients with renal dysfunction [Uchihara et al., 1998; Glue et al., 2000; Gupta et al., 2002; Dienstag and McHutchison, 2006; Ghany et al., 2009] . However, dose reduction of PEG-IFN monotherapy for such patients yielded SVR rates of only approximately 31-37% [Fabrizi et al., 2008; Gordon et al., 2008] .
Recently, a number of new direct-acting antivirals (DAAs), which selectively inhibit HCV proteins such as the nonstructural protein (NS) 3/4A protease, NS5A, and the NS5B polymerase, have been under active development as a replacement for interferonbased therapy. In Japan, daclatasvir and asunaprevir combination therapy was the first interferon-free alloral DAA therapy to be approved for genotype 1 HCV infection [Kumada et al., 2014] . Because daclatasvir and asunaprevir are mainly eliminated through the liver, the combination of these drugs is expected to be an effective therapy for patients with renal dysfunction. The efficacy and safety of daclatasvir and asunaprevir combination therapy for chronic genotype 1 HCV-infected patients on hemodialysis has recently been reported [Kawakami et al., 2016; Suda et al., 2016; Toyoda et al., 2016] . However, the efficacy and safety of the combination therapy for patients with renal dysfunction who are not undergoing hemodialysis are not well known. Recently, sofosbuvir plus ledipasvir treatment was approved and is expected to result in improved SVR rates and shorter duration of therapy for genotype 1 HCV [Mizokami et al., 2015] . Because sofosbuvir is metabolized in the kidney, the drug must be used with caution for patients with eGFR less than 50 ml/min/ 1.73 m 2 . In the present study, we addressed the efficacy and the safety of daclatasvir plus asunaprevir therapy in genotype 1 chronic hepatitis C patients with eGFR less than 50 ml/min/1.73 m 2 without hemodialysis.
MATERIALS AND METHODS

Study Patients
A total of 147 patients with chronic genotype 1 HCV infection who were treated with daclatasvir and asunaprevir combination therapy between September 2014 and August 2015 at Hiroshima University Hospital were enrolled. Inclusion criteria for the study included remaining positive for genotype 1 HCV RNA for 6 months. Patients with decompensated cirrhosis or who were on hemodialysis were excluded. Patients were divided into two groups: normal renal function (estimated glomerular filtration rate [eGFR] ! 50 ml/min/1.73 m 2 ) and renal dysfunction (eGFR <50 ml/min/1.73 m 2 ) ( Table I ). All subjects gave written informed consent to participate in the study according to the process approved by the ethical committee of each hospital and conforming to the ethical guidelines of the 1975 Declaration of Helsinki.
HCV RNA Levels
HCV RNA levels were measured using the COBAS TaqMan HCV test (Roche Diagnostics, Tokyo, Japan). The detection limit for the assay was 1.2 log IU/ml. HCV genotype was determined by sequence determination in the 5 0 non-structural region of the HCV genome, followed by phylogenetic analysis.
Single-Nucleotide Polymorphism (SNP) Genotyping
Each patient was genotyped for ss469415590 in the interferon lambda (IFNL) 4 locus [Fellay et al., 2010; Ochi et al., 2010] . Samples were genotyped using the Illumina Human-Hap610-Quad Genotyping BeadChip or with the Invader or Taqman assays, as described previously [Ochi et al., 2010] .
Detection of Drug-Resistant Substitutions
The amino acid sequences of the NS5A-L31 and -Y93 regions were determined by Invader assay as previously reported [Yoshimi et al., 2015] . The lower detectable limit for the population frequency of NS5A drug resistance-associated variants (RAVs) was approximately 1%.
Therapeutic Protocol
Patients received 24 weeks of treatment with 60 mg once daily of daclatasvir (Daklinza, Bristol-Myers, NY) and 200 mg twice daily of asunaprevir (Sunvepra, Bristol-Myers). Completion of the treatment was defined as completion of 24 weeks of both daclatasvir and asunaprevir.
Measurement of Plasma Daclatasvir and Asunaprevir Concentrations
Plasma concentrations of daclatasvir and asunaprevir at day 5 of the therapy were determined in 53 patients with normal renal function and in 11 patients with renal dysfunction using a high-performance liquid chromatographic apparatus fitted with a mass spectrometer as previously reported [Yuan et al., 2013] . The serum samples were frozen at À80˚C and were thawed at the time of measurement.
Adverse Events
The frequencies of adverse events were compared between patients with normal renal function and with renal dysfunction. In order to determine transaminase elevation, we monitored aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Transaminase elevation after the start of treatment was regarded as an adverse event.
Efficacy of the Treatment
Serum HCV RNA levels were measured 4, 8, 48, 96, and 168 hr after the start of therapy to monitor the early virological response to the therapy. End-oftreatment response (ETR) was defined as undetectable HCV RNA at the end of treatment, and SVR was defined as undetectable HCV RNA at 24 weeks after the end of treatment.
Statistical Analysis
Continuous variables are presented as median and range and were analyzed using the Mann Whitney U-test. Categorical variables were compared using the x 2 or Fisher exact test, as appropriate. All P-values less than 0.05 by the two-tailed test were considered significant. All analyses were performed using IBM SPSS Statistics 22 software (IBM SPSS, Inc., Chicago, IL).
RESULTS
Baseline Patient Characteristics
Baseline characteristics of the 147 patients are shown in Table I . Of 147 patients, 126 patients were classified as having normal renal function, and 21 patients were classified as having renal dysfunction. Patients with renal dysfunction were significantly older, and hemoglobin, AST, ALT, and high density lipoprotein cholesterol were significantly lower, and creatinine and urea acid were significantly higher compared to patients with normal renal function. Pre-treatment NS5A-L31/Y93 RAVs were detected in 23 (18%) patients in the normal renal function group and in 2 (9.5%) patients in the renal dysfunction group. However, the population frequencies of RAVs determined by Invader assay in these patients were relatively low (1-25% in thirteen patients, 25-75% in nine patients, and >75% in three patients).
Daclatasvir and Asunaprevir Concentrations According to Renal Function
We measured plasma daclatasvir and asunaprevir concentrations at 5 days after the start of treatment. Plasma daclatasvir and asunaprevir concentrations were similar between patients with normal renal function and patients with renal dysfunction (239 and 252 ng/ml, 73.1 and 30.2 ng/ml, respectively) ( Fig. 1) , suggesting that renal function is unlikely to have a significant impact on the blood kinetics of daclatasvir and asunaprevir.
Early Response to Daclatasvir and Asunaprevir Therapy
Early virological response to daclatasvir and asunaprevir therapy was analyzed. The combination treatment led to rapid decrease in serum HCV RNA levels. Serum HCV RNA levels decreased by 0.9, 2.0, 3.3, 3.7, and 4.2 log IU/ml, and 1.1, 2.2, 3.2, 3.7, and 4.3 log IU/ml at 4, 8, 48, 96, and 168 hr after the start of treatment in patients with normal renal function and renal dysfunction, respectively ( Fig. 2A) . The early virological response to the therapy was similar between the two groups.
Virological Response to Daclatasvir and
Asunaprevir Therapy ETR was achieved in 122 (96.8%) and 20 (95.2%) patients with normal renal function and renal dysfunction, respectively (Fig. 2B) . After the end of therapy, serum HCV RNA relapse occurred in three patients with normal renal function. SVR was achieved in 119 (94.4%) patients with normal renal function and in 20 (95.2%) patients with renal dysfunction. The virological response to the therapy was similar between the two groups.
Adverse Events
Adverse events were observed in 76.2% and 78.6% of patients with renal dysfunction and normal renal function, respectively (P ¼ 0.544). Table II shows the frequency of adverse events that occurred in more than 5% of patients in each group. The most common adverse event was nasopharyngitis. ALT elevations were observed in 26.9% and 14.3% of patients with normal renal function and renal dysfunction, respectively (P ¼ 0.214). Other adverse events also developed in similar frequencies between the two groups.
Although 78.2% of patients experienced adverse events, treatment discontinuation due to adverse events was required in only two patients (one patient with normal renal function due to ALT elevation at 4 weeks and one patient due to acute heart failure and nephrotic syndrome at 23 weeks). The patient with ALT elevation at 4 weeks achieved SVR.
Serum creatinine and eGFR levels were not significantly changed during and after treatment both in patients with normal renal function as well as patients with renal dysfunction (Fig. 3) .
DISCUSSION
This study examined the efficacy and the safety of daclatasvir plus asunaprevir therapy for genotype 1 HCV-infected patients with renal dysfunction.
We first analyzed the plasma concentrations of daclatasvir and asunaprevir. The concentrations at 5 days after the start of therapy were similar in patients with normal renal function and renal dysfunction. Because daclatasvir and asunaprevir are both metabolized in the liver and eliminated largely in feces [2016a, b] , it does not appear that renal function has a significant effect on serum concentrations of these drugs.
Since renal function showed no effect on serum concentrations of daclatasvir and asunaprevir, early virological response, ETR and SVR rates were similar between patients with normal renal function and renal dysfunction. This is in contrast to expectations for PEG-IFN plus RBV therapy. Because RBV treatment poses the risk of severe anemia in patients with renal dysfunction, it is contraindicated for patients with creatinine clearance <50 ml/min. Therefore, only PEG-IFN monotherapy was available for treatment of patients with renal dysfunction, and efficacy was expected to be low. Conversely, daclatasvir and asunaprevir treatment showed a high SVR rate both in patients with normal renal function as well as patients with renal dysfunction. Therefore, this DAA combination therapy seems to be a safe and effective treatment for genotype 1 HCV-infected patients with renal dysfunction.
Chronic HCV infection is significantly associated with renal dysfunction. Part of this may be related to cryoglobulinemia, a systemic vasculitis that mainly affects small-sized vessels and reflects the expansion of B cells producing pathogenic IgM and IgG with rheumatoid factor activity, and some patients develop membranoproliferative glomerulonephritis (MPGN) [Gumber and Chopra, 1995] . It was reported that elimination of HCV by IFN treatment resulted in an improvement of MPGN [Johnson et al., 1993] . Tsuge et al. [2015] reported a patient whose cryoglobulinemia and renal function had dramatically improved after achieving SVR following daclatasvir plus asunaprevir therapy. Daclatasvir plus asunaprevir seems to be an effective therapy for genotype 1 HCVinfected patients with renal failure due to MPGN.
Patients with NS5A-L31 and/or -Y93 RAVs are more likely to fail to respond to daclatasvir and asunaprevir combination therapy than patients without NS5A RAVs [Kumada et al., 2014] . In a phase 3 clinical trial in Japan, the SVR rate for patients who had NS5A-L31 and/or -Y93 RAVs (determined by direct sequencing analysis) was 43% after 24 weeks of daclatasvir plus asunaprevir combination therapy [Kumada et al., 2014] . In the present study, pre-treatment RAVs were detected by Invader assay in 23 and 2 patients with normal renal function and renal dysfunction, respectively. Although the overall SVR rate for patients with RAVs was 92.0% (23 out of 25 patients), all 11 patients with normal renal function and two patients with renal dysfunction with RAVs present at low frequency (approximately 1-25%) achieved SVR. These results indicate that even though NS5A-L31 and -Y93 RAVs were detected, a high SVR rate may still be expected as long as only patients with NS5A-L31 or -Y93 RAVs at low frequency are treated with daclatasvir plus asunaprevir, regardless of renal function.
As the concentrations of daclatasvir and asunaprevir were similar between patients with normal renal function and renal dysfunction, the frequencies of adverse events were also similar between the two groups. Headache occurred with higher frequency in patients with normal renal function compared to patients with renal dysfunction (24.6% and 4.8%, respectively). The reason is unclear. It is possible that patients with renal dysfunction have a high pain threshold because renal dysfunction is associated with headache. Although 78.2% of patients developed adverse events, the treatment was discontinued in only one patient in each group. No significant changes in renal function during or after treatment were observed in patients regardless of renal function (Fig. 3) . These results suggest that the safety of daclatasvir plus asunaprevir therapy is relatively high, even for patients with renal dysfunction.
In conclusion, patients with renal dysfunction have a similar virological response rate and a similar tolerance to daclatasvir plus asunaprevir therapy as patients with normal renal function. This combination treatment should be considered as a safe and effective treatment option for genotype 1 HCV-infected patients with renal dysfunction and RAVs present at low frequency.
